Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
REC611C301
Phase 2 mab completed
Quick answer
Part1:Recombinant two-component COVID-19 vaccine (CHO cell) for COVID-19 is a Phase 2 program (mab) at Jian Li with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jian Li
- Indication
- COVID-19
- Phase
- Phase 2
- Modality
- mab
- Status
- completed